📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-13 17:47
453 analysed today
453
Today
133,342
All-time analysed
40,106
Positive
6,279
Negative
79,144
Neutral
7,745
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
8 announcements match the current filters (relevance ≥ 5).
81% Revenue Growth in Q1 FY27; Medico Remedies Reports ₹69.40 Cr Revenue
Medico Remedies Limited reported a strong performance for Q1 FY27, with revenue from operations surging 81.4% YoY to ₹69.40 cr. Net profit grew 38.5% YoY to ₹2.52 cr, although margins appear slightly compressed compared to the top-line growth. A significant shift was observed in the sales mix, with domestic sales jumping to ₹26.34 cr from just ₹2.74 cr in the preceding quarter. The board also approved the re-appointment of key promoter-directors and an increase in the Managing Director's remuneration.
Confidence: HIGH
What changedThe company achieved record quarterly revenue and significantly diversified its geographical revenue base by increasing domestic market penetration.
Why it mattersThe strong top-line growth validates the company's expansion strategy, though the shift toward domestic sales and increased management remuneration are key factors to watch for margin impact.
Revenue (Q1 FY27): ₹69.40 crNet Profit (Q1 FY27): ₹2.52 crYoY Revenue Growth: 81.4%Domestic Sales (Q1 FY27): ₹26.34 crExport Sales (Q1 FY27): ₹42.70 cr
📅 Short termThe stock is likely to react positively to the substantial YoY revenue and profit growth reported for the June quarter.
📈 Long termThe structural shift toward domestic sales and the planned expansion into beta-lactam products could re-rate the business if execution remains consistent.
⚠ Risk flags
- Significant shift in sales mix from exports to domestic
- High customer concentration (top 5 historically 56%)
- Increase in Managing Director remuneration
Key Highlights
Revenue from operations increased by 81.4% YoY to ₹69.40 cr from ₹38.25 cr in Q1 FY26.
Net profit for the quarter rose 38.5% YoY to ₹2.52 cr compared to ₹1.82 cr in the same period last year.
Domestic sales saw a massive sequential jump to ₹26.34 cr in Q1 FY27 from ₹2.74 cr in Q4 FY26.
Export sales moderated to ₹42.70 cr in Q1 FY27 from ₹53.64 cr in Q4 FY26, now representing 61.5% of total sales.
Board approved the re-appointment of Chairman Haresh Mehta and WTD Rishit Mehta for 3-year terms starting September 18, 2026.
👀 What to Watch
Investors should monitor the sustainability of the sudden surge in domestic sales and whether this shift from an export-heavy model (previously 95% exports) impacts long-term operating margins.
₹13.38 Cr Order Win: Medico Remedies to Supply Dominican Republic Government
Medico Remedies has secured a government supply order from PROMESE/CAL, Dominican Republic, valued at approximately ₹13.38 Crores (USD 1.41 million). The contract involves the supply of tablets, capsules, and dry syrups to the National Public Health System. The company is required to complete the entire order within a 3-month timeframe. This win is material, representing roughly 22.8% of the company's Dec 2025 quarterly revenue of ₹58.68 Crores.
Confidence: HIGH
What changedMedico Remedies secured a new international government contract for pharmaceutical supplies in the Dominican Republic.
Why it mattersThis order provides immediate revenue visibility and reinforces the company's strategy of expanding in pharmerging markets, leveraging its 95% export-oriented business model.
Order Value (INR): ₹13.38 CroresExecution Timeline: 3 monthsOrder vs Dec 2025 Revenue: ~22.8%Export Revenue Share: 95%Promoter Holding: 61.38%
📅 Short termThe stock may react positively to the order win, which represents a significant portion of quarterly turnover and provides a clear revenue catalyst for the next quarter.
📈 Long termContinued success in international government tenders could lead to a more stable order book, though high customer concentration (top 5 = 56%) remains a structural risk to monitor.
⚠ Risk flags
- Foreign exchange volatility (95% exports)
- Tight 3-month execution timeline
- High customer concentration (top 5 = 56% of revenue)
Key Highlights
Order value of USD 1,406,450, equivalent to approximately ₹13.38 Crores
Full order execution mandated within a short 3-month window
Client is PROMESE/CAL, the centralized health logistics agency for the Dominican Republic
Product scope includes tablets, capsules, and dry syrups
Order represents ~22.8% of the company's Dec 2025 quarterly revenue
👀 What to Watch
Watch for the impact on the next two quarters' revenue and margins, especially considering the company's 95% export exposure and potential FX volatility during the 3-month execution period.
₹42 Cr Bank Facilities Rated; CRISIL Reaffirms BBB-/Stable for Medico Remedies
CRISIL Ratings has reaffirmed Medico Remedies Limited's long-term rating at 'CRISIL BBB-/Stable' and short-term rating at 'CRISIL A3'. Notably, the total rated bank facilities have been enhanced to ₹42 crore from the previous ₹19 crore, providing the company with additional credit headroom. With a current debt of ₹19 crore against a net worth of ₹76 crore (D/E of 0.25), the company maintains a conservative leverage profile. The enhancement in rated facilities likely supports the company's stated strategy to expand its manufacturing footprint and product range in export markets.
Confidence: HIGH
What changedThe total credit facilities rated by CRISIL have been increased from ₹19 crore to ₹42 crore, while the credit ratings themselves remain unchanged.
Why it mattersThe reaffirmation of the 'Stable' outlook confirms the company's creditworthiness, while the increased limits provide the necessary liquidity to fund its planned expansion into beta-lactam products and new export regions.
Total Rated Facilities: ₹42 CrorePrevious Rated Amount: ₹19 CroreLong-term Rating: CRISIL BBB-/StableShort-term Rating: CRISIL A3Debt to Net Worth Ratio: 0.25
📅 Short termThe reaffirmation is expected to have a neutral impact on the stock price in the short term as it represents status quo on credit quality.
📈 Long termThe expanded credit limits support the company's long-term growth target of 11%, facilitating the production of new product ranges like Amoxicillin with potassium clavulanate.
⚠ Risk flags
- High customer concentration (top 5 clients = 56% of revenue)
- Significant foreign exchange risk (95% export revenue)
- Potential liquidity strain if working capital cycle exceeds 200 GCA days
Key Highlights
Total bank loan facilities rated increased to ₹42 crore from ₹19 crore
Long-term rating reaffirmed at CRISIL BBB-/Stable for ₹19 crore term loan and ₹18 crore packing credit
Short-term rating reaffirmed at CRISIL A3 for ₹5 crore non-fund based facilities
Company maintains a healthy ROCE of 23.0% and a low Debt/Equity ratio of 0.25
95% of sales are derived from exports, making the company sensitive to foreign exchange fluctuations
👀 What to Watch
Investors should monitor the utilization of the newly enhanced ₹42 crore credit limit and its impact on interest costs and the working capital cycle, particularly given the risk of GCA days stretching beyond 200 days.
Medico Remedies FY26 Net Profit Rises 30% to ₹13.13 Cr; Revenue Up 37% YoY
Medico Remedies Limited reported a robust financial performance for the fiscal year ended March 31, 2026. Annual revenue from operations grew significantly by 36.7% to ₹206.38 crore, while net profit increased by 30% to reach ₹13.13 crore. The fourth quarter (Q4 FY26) also showed strong momentum with a net profit of ₹5.86 crore compared to ₹4.34 crore in the corresponding quarter of the previous year. The company's auditors have issued a clean, unmodified opinion on these results.
Key Highlights
Annual revenue from operations increased to ₹20,637.73 lakhs in FY26 from ₹15,094.06 lakhs in FY25.
Net profit for the full year grew 30% YoY to ₹1,312.52 lakhs.
Q4 FY26 revenue stood at ₹5,680.77 lakhs, representing a 37.5% growth over Q4 FY25.
Earnings Per Share (EPS) improved to ₹1.58 for FY26 from ₹1.22 in the previous fiscal year.
Total expenses for the year rose to ₹19,425.12 lakhs, driven largely by a 33% increase in material costs.
👀 What to Watch
Investors should take note of the company's strong growth trajectory in both revenue and profitability. While the growth is impressive, monitoring the rising 'Other Expenses' and material costs will be crucial to ensure margin stability in future quarters.
Medico Remedies Approves Unaudited Financial Results for Q3 FY26
Medico Remedies Limited held a board meeting on February 12, 2026, to approve the unaudited standalone financial results for the quarter and period ended December 31, 2025. The meeting was conducted efficiently, lasting only 30 minutes from 5:00 PM to 5:30 PM. The board also reviewed and approved the Auditors' Limited Review Report for the same period. This filing marks the completion of the company's regulatory requirements for the third quarter of the 2025-26 fiscal year.
Key Highlights
Board approved Unaudited Standalone Financial Results for the quarter ended December 31, 2025.
The meeting was held on February 12, 2026, and concluded within 30 minutes.
Auditors' Limited Review Report was formally considered and approved by the board.
Compliance confirmed under Regulation 30 of SEBI Listing Obligations and Disclosure Requirements.
👀 What to Watch
Investors should examine the detailed financial tables to evaluate revenue growth and margin performance compared to previous quarters. Monitor the stock for any price movement following the formal release of these earnings figures.
Medico Remedies Approves Unaudited Financial Results for Quarter Ended Dec 31, 2025
Medico Remedies Limited has officially approved its unaudited standalone financial results for the quarter ended December 31, 2025. The board meeting was held on February 12, 2026, and concluded within 30 minutes, signifying a routine regulatory approval process. While the specific financial figures were not detailed in the summary letter, the announcement confirms the completion of the limited review by auditors. Investors should now look to the detailed financial tables for specific revenue and margin performance.
Key Highlights
Board approved unaudited standalone financial results for the quarter ended December 31, 2025.
The board meeting was conducted on February 12, 2026, from 5:00 P.M. to 5:30 P.M.
The results were submitted along with the Auditors’ Limited Review Report as per SEBI regulations.
The filing covers the performance for the third quarter of the 2025-26 fiscal year.
👀 What to Watch
Investors should examine the full financial statements for specific growth in net profit and revenue. Compare the Q3 performance against previous quarters to assess the company's operational trajectory.
Medico Remedies Bags ₹37.18 Crore Order from UP Medical Supplies Corporation
Medico Remedies Limited has secured a significant domestic supply order worth approximately ₹37.18 crore from the Uttar Pradesh Medical Supplies Corporation Limited. The contract involves the supply of multiple drugs to the Government of Uttar Pradesh's centralized distribution entity. The company is expected to complete the full supply of the order by October 31, 2026. This government contract provides strong revenue visibility for the company over the next 20 months.
Key Highlights
Total order value is ₹37,17,62,439 (approximately ₹37.18 crore)
Contract awarded by Uttar Pradesh Medical Supplies Corporation Limited, a GoUP entity
The order involves the supply of multiple drugs for state-wide distribution
Project completion timeline is set for October 31, 2026
👀 What to Watch
Investors should view this as a positive development for revenue growth and monitor the company's ability to maintain margins on government-tendered contracts. Watch for timely execution updates as the October 2026 deadline approaches.
Medico Remedies Secures ₹73.23 Crore Order from UP Medical Supplies Corp
Medico Remedies Limited has bagged a significant domestic order worth ₹73.23 crore from the Uttar Pradesh Medical Supplies Corporation Limited, a Government of Uttar Pradesh entity. The contract involves the supply of Azithromycin 500mg tablets across the state's healthcare network. The company is mandated to complete the full supply of the order by October 31, 2026. This large-scale government contract provides strong revenue visibility and validates the company's standing in the pharmaceutical supply chain.
Key Highlights
Total order value is approximately ₹73,23,16,646 for drug supplies
Contract involves the supply of Azithromycin 500mg tablets to the UP Government
The execution timeline for the full order is set until October 31, 2026
The order is awarded by a domestic government entity with no promoter interest involved
👀 What to Watch
Investors should view this as a positive development for the company's order book and revenue growth. Monitor the company's ability to maintain margins while executing this large-scale government contract.
